Prof. Kuaile Zhao 赵快乐
Chief Physician, Professor
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation therapy and comprehensive treatment for thoracic tumors, including esophageal cancer, lung cancer, and mediastinal tumors.
Dr. Zhao holds a PhD in Oncology from Fudan University and completed advanced training at MD Anderson Cancer Center (2006–2007). A Chief Physician and Professor, Dr. Zhao has published over 100 academic papers and received the Ministry of Education First Prize for Scientific and Technological Progress in 2006.
Professional roles
- Member, Esophageal Cancer Professional Committee, China Anti-Cancer Association
- Member, Thoracic Tumor Professional Committee, Shanghai Anti-Cancer Association
- Editorial Board Member, Chinese Journal of Radiation Oncology
- Member, Tumor Staging Professional Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Zhao Kuaile). Papers usually list the name as Kuaile Zhao or Zhao K.
Selected publications
109 papers on PubMed matched by name and affiliation; 50 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Transl Med, 2026 (senior author): Nrf2 deficiency converts the ESCC microenvironment into an immunologically active state via the GPX2-ICD-DC signaling path. PubMed 42332706
- EBioMedicine, 2026 (senior author): The AGPS regulatory variant rs113671272 confers esophageal squamous cell carcinoma susceptibility through allele-specific MEIS3 binding and NF-κB activation in Chinese populations. PubMed 41950565
- Future Oncol, 2026 (senior author): Precision palliative care in advanced/recurrent esophageal cancer patients treated with anti-PD-1/PD-L1 immunotherapy (ESO-Shanghai 25): a randomized, phase III Trial. PubMed 41778625
- Clin Transl Radiat Oncol, 2026 (senior author): Postoperative chemoradiotherapy for esophageal squamous cell Carcinoma: Results from ESO-Shanghai 17 and joint analyses for phase II clinical trials. PubMed 41531940
- Br J Cancer, 2026 (senior author): PD-1 inhibitor improves radiosensitivity by tumor vessel normalization. PubMed 41454187
- Ther Adv Med Oncol, 2026 (senior author): The role of thoracic radiotherapy in the setting of immunotherapy in polymetastatic esophageal squamous cell carcinoma: a multi-center cohort study. PubMed 41696558
- Cancer Immunol Immunother, 2025 (senior author): Comparative analysis of immunochemotherapy with versus without radiation therapy for stage IVB esophageal squamous cell carcinoma confined to non-regional nodal metastases: a multicenter propensity score matching study. PubMed 41251846
- Oncologist, 2025 (senior author): Phase II trial of radiotherapy plus Huachansu in elderly or chemotherapy-ineligible patients with locally advanced esophageal squamous cell carcinoma. PubMed 41021440
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion